VTAK · Flyte Aviation, Inc.

Catheter Precision consummated the Series C-2 Closing on April 21, 2026, raising $3.47 million in gross proceeds from accredited investors via previously disclosed purchase agreements dated February 6 and March 6, 2026. This followed stockholder approval on April 15, 2026, satisfying NYSE American requirements for the potential issuance of common shares upon conversion. The Series C-2 Preferred carries an initial $0.883 conversion price with a $0.35 floor (waivable by the Company) and 4.99% beneficial ownership blocker, adjustable to 9.99% with notice. Concurrently, on April 20, 2026, the Company issued Series D Preferred as acquisition consideration for Flyte: 5,250 shares to SEG Jets for 19.98% of Flyte and 5,778 shares to Creatd for the remaining 80.02%, per prior agreements. Series D has a $1.1038 initial conversion price, adjustable post-registration effectiveness to the lower of prior price or Applicable Price, also with $0.35 floor and ownership limits. Both series were filed with Delaware on April 17, 2026, designating 3,470 and 11,028 shares respectively from authorized preferred stock. These senior securities rank ahead of common stock for dividends and liquidation, with conversion post-approval introducing dilution risk to existing common holders. Dawson James served as placement agent for Series C-2, receiving customary fees. Securities issued under Section 4(a)(2) and Rule 506(b) exemptions, with restrictive legends.